BioWorld Asia

March 29, 2006

NicOx Expands Merck Deal For Up To $350M

A research collaboration that started in August 2003 came full circle when French company NicOx SA granted Merck & Co. Inc. exclusive worldwide development and marketing rights to nitric oxide-donating drugs for hypertension. (BioWorld International) Read More

Pharming Acquiring DNAge: Milestones, EUR15M In Shares

Mutant Yeast Show Details Of Telomere Maintenance

Europe’s Biotech Industry Energized By EU Summit

PanGenetics Brings In EUR13M For Antibody Development

Pfizer Licenses, Invests In Noxxon’s Spiegelmer Drugs

Biotech Pipelines Sitting Unexploited’ In Australia

Speedel Raises CHF79.7M In Sale Of Treasury Shares

BioSystems Licenses Biomarker Technology From Northeastern

Diagnostics Seen As Hope For Future Of Health Care

Biofusion, NPI Set UP £10M Fund To Fuel Biotech Firms

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Voyager’s gene therapy reduces tau levels in AD models

BioWorld Science

At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...